Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott

Executive Summary

Agreement to develop and market neurological agent NPS 1776 signed with NPS Pharmaceuticals. NPS 1776 is an alifatic amide with structural similarities to valproic acid (Abbott's Depakote) that may be used to treat bipolar mood disorder and epilepsy. "NPS 1776 has pharmacologically significant structural distinctions that will provide a better safety profile in comparison to valproic acid such as lack of birth defect potential and liver damage," NPS' March 20 SEC filing states. NPS has completed two Phase I safety and tolerability trials on NPS-1776, the company said
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS035776

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel